Equity Details
Price & Market Data
Price: $3.52
Daily Change: +$0.77 / 21.88%
Daily Range: $2.99 - $4.27
Market Cap: $12,642,667
Daily Volume: 45,853,109
Performance Metrics
1 Week: 177.4%
1 Month: 218.1%
3 Months: 126.4%
6 Months: -63.20%
1 Year: -84.94%
YTD: -16.61%
About GeoVax Labs, Inc. (GOVX)
Understand GeoVax Labs, Inc. (GOVX)'s current market standing. Current price: 3.52, daily change: +$0.77 / 21.88%. Market cap: 12,642,667. Detailed performance for all periods.
Company Details
Employees: 19
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
